Brucellosis in a patient with Crohn's disease treated with infliximab: A case report.

Autor: Altuwaijri M; Division of Gastroenterology, Department of Medicine, College of Medicine, King Saud University, Riyadh, Saudi Arabia. Electronic address: maltuwaijri@ksu.edu.sa., Alkhraiji N; Department of Medicine, College of Medicine, King Saud University, Riyadh, Saudi Arabia. Electronic address: Nasser.alkhraiji@gmail.com., Almasry M; Department of Medicine, College of Medicine, King Saud University, Riyadh, Saudi Arabia., Alkhowaiter S; Division of Gastroenterology, Department of Medicine, College of Medicine, King Saud University, Riyadh, Saudi Arabia., Al Amaar N; Division of Gastroenterology, Department of Medicine, College of Medicine, King Saud University, Riyadh, Saudi Arabia. Electronic address: nalammar2@ksu.edu.sa., Alotaibi A; Division of Gastroenterology, Department of Medicine, College of Medicine, King Saud University, Riyadh, Saudi Arabia. Electronic address: Ammalotaibi@ksu.edu.com.
Jazyk: angličtina
Zdroj: Arab journal of gastroenterology : the official publication of the Pan-Arab Association of Gastroenterology [Arab J Gastroenterol] 2024 Mar 21. Date of Electronic Publication: 2024 Mar 21.
DOI: 10.1016/j.ajg.2024.03.001
Abstrakt: Crohn's disease (CD) is an inflammatory disease that can affect any part of the gastrointestinal tract and presents with myriad symptoms. Various treatments, including biological treatments, are available. The use of biologics increases the risk of opportunistic infections, with no association with serious infections (1). To the best of our knowledge, there are no established recommendations or case studies for patients with CD infected with Brucella being actively treated with biologics and immunomodulators to date. Herein, we report the first case of brucellosis diagnosed in a patient with CD treated with biologics and immunomodulators. A 40-year-old man had been treated with anti-tumour necrosis factor (anti-TNF) drugs, namely, infliximab and azathioprine, for CD for the past eight years. During a follow-up visit, the patient complained of loss of appetite, fever, weight loss, and joint discomfort. The patient reported a history of raw milk consumption. Blood cultures indicated the growth of Brucella species. Infliximab and azathioprine were held, and brucellosis treatment was initiated, including rifampin 600 mg once daily, doxycycline 100 mg twice daily, and streptomycin 1 g intramuscularly daily. A multidisciplinary team comprising gastroenterologists and infectious disease specialists decided to initiate brucellosis treatment and resume biologics and immunomodulators 4 weeks after starting Brucella treatment.
Competing Interests: Declaration of competing interests The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2024 Pan-Arab Association of Gastroenterology. Published by Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: